Cell to Cure ApS: Financial statements 2021
CVR: 39401975
Source: annual report 2021, Danish Business Authority
01/09/2020 – 31/08/2021
Cell to Cure ApS (CVR 39401975) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 294,954 and a net result of DKK 217,939 compared with DKK 405,000 the year before. That is a decrease of 43.6% compared with the year before. Equity in the 2021 report amounted to DKK 694,568. The solvency ratio was 68.5%.
- Gross Profit
- DKK 294,954
- Profit/Loss
- DKK 217,939
- Equity
- DKK 694,568
- Total Assets
- DKK 1,014,406
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | 295 t. | 218 t. | 695 t. | 0 |
| 2020 | - | 523 t. | 405 t. | 462 t. | 0 |
Official annual report
Find more companies like Cell to Cure ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorAbout Cell to Cure ApS
Cell to Cure ApS is a Danish company of the type Anpartsselskab based in Birkerød, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Cell2Cure ApS. The management consists of Jens Kastrup, Annette Ekblond and Mandana Haack-Sørensen. The board consists of Anders Østergaard (chair), Annette Ekblond, Jens Kastrup and Mandana Haack-Sørensen. The company's owners include MEDIC ADVICE ApS, Endeavour Cells ApS and Ekblond.ApS. The company has 5 employees (2026). In 2025, the company reported a gross profit of DKK -3,076,475 and a net result of DKK -9,792,604. Equity in the 2025 report amounted to DKK -1,179,103.